ASCO 2012: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial
Tag: Tivozanib
Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
Authors: Dmitry A. Nosov, Brooke Esteves, Oleg N. Lipatov, Alexei A. Lyulko, A. A. Anischenko, Raju T. Chacko, Dinesh C. Doval, Andrew Strahs, William J. Slichenmyer, Pankaj Bhargava. Click here for link to article.
AACR 2012: The Effect of Food on the Pharmacokinetics of Tivozanib
AACR 2012: The Effect of Food on the Pharmacokinetics of Tivozanib
AACR-NCI-EORTC 2011: A Phase I Study to Evaluate the Absorption, Metabolism and Excretion of the Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Tivozanib
AACR-NCI-EORTC 2011: A Phase I Study to Evaluate the Absorption, Metabolism and Excretion of the Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Tivozanib
AACR-NCI-EORTC 2011: A Phase I QTc Study of Tivozanib in Patients with Advanced Solid Tumors
AACR-NCI-EORTC 2011: A Phase I QTc Study of Tivozanib in Patients with Advanced Solid Tumors
Biological and Clinical Activity of Tivozanib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4 Week on, 2 Week off Schedule in Patients With Advanced Solid Tumors.
Authors: Ferry A. L. M. Eskens, Maja J. A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, Jaap Verweij. Click here for link to article.
AACR-NCI-EORTC 2011: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade
AACR-NCI-EORTC 2011: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade
EMUC 2011 – Results from Phase 1 trial of tivozanib combined with temsirolimus in patients with RCC
EMUC 2011 – Results from Phase 1 trial of tivozanib combined with temsirolimus in patients with RCC
ASCO 2011: Final Analysis of the Phase 2 Randomized Discontinuation Trial of Tivozanib (AV-951) Versus Placebo in Patients With Renal Cell Carcinoma
ASCO 2011: Final Analysis of the Phase 2 Randomized Discontinuation Trial of Tivozanib (AV-951) Versus Placebo in Patients With Renal Cell Carcinoma
ASCO 2011: Results From a Phase 1 Trial of Tivozanib (AV-951) Combined With Temsirolimus Therapy in Patients With Renal Cell Carcinoma
ASCO 2011: Results From a Phase 1 Trial of Tivozanib (AV-951) Combined With Temsirolimus Therapy in Patients With Renal Cell Carcinoma